Results 211 to 220 of about 280,456 (250)
Some of the next articles are maybe not open access.
Atherosclerosis Supplements, 2019
In Austria, about 12 patients per 1 million inhabitants are treated currently with lipoprotein (LP-) apheresis. In 2016 it has been suggested, that about 5000 patients were treated worldwide with LP-apheresis, more than half of them in Germany. Regular LP-apheresis aims to decrease apolipoprotein B-rich lipoproteins and to reduce cardiovascular events.
Theresa, Berent +3 more
openaire +2 more sources
In Austria, about 12 patients per 1 million inhabitants are treated currently with lipoprotein (LP-) apheresis. In 2016 it has been suggested, that about 5000 patients were treated worldwide with LP-apheresis, more than half of them in Germany. Regular LP-apheresis aims to decrease apolipoprotein B-rich lipoproteins and to reduce cardiovascular events.
Theresa, Berent +3 more
openaire +2 more sources
Journal of clinical apheresis, 2021
Lipoprotein apheresis (LA) is a safe method of reducing atherogenic lipoproteins and improving cardiovascular (CV) outcomes. We aimed to assess the reductions in low‐density lipoprotein cholesterol (LDL‐C) and lipoprotein (a) [Lp(a)] levels in patients ...
A. Mickiewicz +7 more
semanticscholar +1 more source
Lipoprotein apheresis (LA) is a safe method of reducing atherogenic lipoproteins and improving cardiovascular (CV) outcomes. We aimed to assess the reductions in low‐density lipoprotein cholesterol (LDL‐C) and lipoprotein (a) [Lp(a)] levels in patients ...
A. Mickiewicz +7 more
semanticscholar +1 more source
Journal of clinical apheresis, 2021
Lipoprotein apheresis (LA) tolerability is a key factor for the utilization of this therapy. Common reactions to LA are hypotension and nausea.
Ethan Alexander +3 more
semanticscholar +1 more source
Lipoprotein apheresis (LA) tolerability is a key factor for the utilization of this therapy. Common reactions to LA are hypotension and nausea.
Ethan Alexander +3 more
semanticscholar +1 more source
Low Density Lipoprotein Apheresis for Treatment of Focal Segmental Glomerulosclerosis
Hemodialysis international. International Symposium on Home HemodialysisFocal segmental glomerulosclerosis (FSGS) has become one the leading causes of kidney disease in the United States. With the incidence of FSGS rising over the past decade, capable treatment options have been a large focus in research.
Maximilian Dawson +7 more
semanticscholar +1 more source
Current Opinion in Lipidology, 2010
Lipoprotein apheresis is being performed with increasing frequency, but better data collection and recording of clinical outcomes are needed. Setting up registries would facilitate this process.This review appraises recent articles that discuss the need for national registries and requirements for setting them up, the efficacy of lipoprotein apheresis ...
openaire +2 more sources
Lipoprotein apheresis is being performed with increasing frequency, but better data collection and recording of clinical outcomes are needed. Setting up registries would facilitate this process.This review appraises recent articles that discuss the need for national registries and requirements for setting them up, the efficacy of lipoprotein apheresis ...
openaire +2 more sources
Is Lipoprotein (a)—Apheresis Useful?
Therapeutic Apheresis and Dialysis, 2005Abstract: Numerous epidemiological investigations have shown the importance of cholesterol, and in particular low density lipoprotein (LDL), and of the lipoproteins in the development of coronary sclerosis. A continuing relationship between cholesterol levels and coronary morbidity has been established.
openaire +2 more sources
Therapeutic apheresis and dialysis
Extracellular vesicles (EVs) have been identified as playing a role in atherosclerosis.
Sophie Schröder +3 more
semanticscholar +1 more source
Extracellular vesicles (EVs) have been identified as playing a role in atherosclerosis.
Sophie Schröder +3 more
semanticscholar +1 more source
Pleiotropic effects of regular lipoprotein-apheresis
Atherosclerosis Supplements, 2017Lipoprotein(LP)-apheresis is the treatment of choice in patients suffering from severe familial hypercholesterolemia. A wide range of mechanisms has been claimed to be responsible for the known clinical benefit.Patients suffering from heterozygous familial hypercholesterolemia undergoing LP-apheresis either with direct adsorption of lipoproteins (DALI)
Helmut, Sinzinger +2 more
openaire +2 more sources
Low‐density Lipoprotein Apheresis: An Overview
Therapeutic Apheresis and Dialysis, 2003Abstract: Atherosclerosis with myocardial infarction, stroke, and peripheral cellular disease still maintains its position at the top of morbidity and mortality statistics in industrialized nations. Established risk factors widely accepted are smoking, arterial hypertension, diabetes mellitus, and central obesity.
Rolf, Bambauer +2 more
openaire +2 more sources
Indications for low-density lipoprotein apheresis
The American Journal of Cardiology, 1994Low-density lipoprotein (LDL) apheresis offers an additional approach to lipid lowering in patients with severe hypercholesterolemia who fail to respond adequately to diet and drug therapy. Well-defined criteria for patient selection have yet to be established for LDL apheresis.
B R, Gordon +3 more
openaire +2 more sources